NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Forecast & News

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.01. View CymaBay Therapeutics' Earnings History.

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CymaBay Therapeutics.

13 brokerages have issued 12 month price targets for CymaBay Therapeutics' stock. Their forecasts range from $2.00 to $18.00. On average, they expect CymaBay Therapeutics' stock price to reach $6.95 in the next year. This suggests a possible upside of 290.7% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CymaBay Therapeutics.

News stories about CBAY stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. CymaBay Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near future. View News Stories for CymaBay Therapeutics.

Some companies that are related to CymaBay Therapeutics include BioDelivery Sciences International (BDSI), Prothena (PRTA), Cue Biopharma (CUE), BioSpecifics Technologies (BSTC), Sinovac Biotech (SVA), Beyondspring (BYSI), Organogenesis (ORGO), Progenics Pharmaceuticals (PGNX), Innate Pharma (IPHYF), Merus (MRUS), OrganiGram (OGI), AnaptysBio (ANAB), Mallinckrodt (MNK), ProQR Therapeutics (PRQR) and Morphic (MORF).

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

CymaBay Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Engine Capital Management LP (7.25%), Boxer Capital LLC (2.91%), State Street Corp (2.05%), Citigroup Inc. (1.96%), Geode Capital Management LLC (1.50%) and Renaissance Technologies LLC (0.62%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

CBAY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Bank of America Corp DE, UBS Group AG, Charles Schwab Investment Management Inc., Cubist Systematic Strategies LLC, Credit Suisse AG and National Asset Management Inc.. View Insider Buying and Selling for CymaBay Therapeutics.

CBAY stock was acquired by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Boxer Capital LLC, Acadian Asset Management LLC, Renaissance Technologies LLC, Citigroup Inc., Alambic Investment Management L.P., Jacobs Levy Equity Management Inc. and Goldman Sachs Group Inc.. View Insider Buying and Selling for CymaBay Therapeutics.

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBAY stock can currently be purchased for approximately $1.78.

CymaBay Therapeutics has a market capitalization of $122.29 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics.

The official website for CymaBay Therapeutics is http://www.cymabay.com/.

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]